Skip to content

Earnings call

Acutaas Chemicals Q4 FY25 earnings call: Ami Organics Limited anticipates continued growth in its CDMO business in FY '26, bolstered by increasing demand and new CDMO contracts

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Ami Organics Limited anticipates continued growth in its CDMO business in FY '26, bolstered by increasing demand and new CDMO contracts. Ami Organics Limited's electrolyte additives business is scheduled to commence production from a new brownfield plant at Jhagadia site in the second half of FY '26. Ami Organics Limited crossed the INR1,000 crore revenue threshold in FY '25. Ami Organics Limited has sufficient cash on hand to fund its upcoming-year capex through QIP proceeds and internal accruals of FY '25.

The numbers management gave

Results

  • Ami Organics Limited crossed the INR1,000 crore revenue threshold in FY '25.
    Show source
    Coming to Ami Organics performance for the year, I'm delighted to report that FY '25 marks a landmark year for Ami Organics as we crossed the INR1,000 crore revenue threshold.
  • Ami Organics Limited's Pharmaceutical Intermediates segment delivered revenue of INR273 crores in Q4 FY '25, growth of around 44% Y-o-Y; for the full year, it delivered revenue of INR854 crores, growth of 50% Y-o-Y, with CDMO business a key growth driver and steady growth momentum in the Pharma Intermediates business.
    Show source
    This segment delivered revenue of INR273 crores in Q4 FY '25, which is a strong growth of around 44% Y-o-Y. For the full year, Pharma Intermediates business delivered revenue of INR854 crores, which is stellar 50% growth Y-o-Y. CDMO business was a key growth driver for this business, whereas Pharma Intermediates business continues steady growth momentum.
  • Ami Organics Limited's Specialty Chemicals segment reported flattish revenue of INR36 crores during the quarter.
    Show source
    This segment reported flattish revenue of INR36 crores during the quarter.
  • Ami Organics Limited's Specialty Chemicals business generated revenue of INR153 crores for the full year, growth of 2% Y-o-Y; overall business was flattish due to degrowth in BFC business offset by growth in commodity chemical business.
    Show source
    For the full year, the revenue were INR153 crores, which is a 2% growth Y-o-Y. While the overall business looked flattish for the year, this was purely driven by the degrowth in BFC business, which was offset by growth in commodity chemical business.
  • Ami Organics Limited's Q1 is typically its weakest quarter, with revenue steadily increasing sequentially until Q4, which is always the strongest quarter; H1 contributes around 40% of total top line and H2 around 60% of total year revenue, and lower top line means H1 may have lower margins in Q1 and Q2.
    Show source
    This pattern results in H1 contributing around 40% of the total top line, while H2 accounts for around 60% of the total year revenue.
  • Ami Organics Limited's revenue from operations reached INR308.5 crores for the quarter, growth of 37.1% Y-o-Y and 12.2% Q-o-Q; gross profit was INR146 crores, up 62.3% compared with the same period last year.
    Show source
    Revenue from the operations for the quarter reached to INR308.5 crores, representing 37.1% growth and Y-o-Y 12.2% Q-o-Q. Gross profit for the quarter was INR146 crores, reflecting 62.3% increase compared to the same period last year.
Show 14 more statements

Results

  • Ami Organics Limited’s gross margin was 47.3% in Q4FY25, compared with 40.0% in Q4FY24, expanded by 734 basis points Y-o-Y and 108 basis points sequentially, driven by better product mix, and 45.2% in FY25, compared with 42.6% in FY24.
    Show source
    The gross margin expanded by 734 basis points Y-o-Y and 108 basis points sequentially to 47.3%.
  • Ami Organics Limited's PAT for the quarter was INR62.7 crores, almost 2.5x the PAT of INR25.7 crores in Q4 FY '24.
    Show source
    PAT for the quarter was INR62.7 crores, which grew almost 2.5x compared to the PAT of INR25.7 crores in Q4 FY '24.
  • Ami Organics Limited's PAT margin for the quarter was 20.3%, compared with 11.4% in Q4FY24, an expansion of 892 basis points Y-o-Y and 380 basis points Q-o-Q; FY25 PAT margin was 15.9%, compared with 11.3% in FY24; FY24 PAT Margin is adjusted for Exceptional Items.
    Show source
    PAT margin for the quarter were 20.3%, which saw an expansion of 892 basis points Y-o-Y and 380 basis points Q-o-Q. Moving to the performance for FY '25.
  • Ami Organics Limited's EBITDA for FY '25 was INR232.1 crores, up 80.6% Y-o-Y, and PAT was INR160.4 crores, almost double the adjusted PAT for the same period last year.
    Show source
    EBITDA for the FY '25 was INR232.1 crores, up 80.6% Y-o-Y. PAT for FY '25 was at INR160.4 crores, which was almost double when compared to the adjusted PAT for the same period last year.
  • Ami Organics Limited's working capital was 114 days during FY '25, compared with 116 days in FY '24, driven by improved inventory days and stable receivable days.
    Show source
    I'm happy to share that even with robust growth, we are able to control our working capital, which was 114 days during FY '25 as against 116 days in FY '24.
  • Ami Organics Limited generated cash flow from operations of INR118 crores during FY '25, around 51% of its EBITDA, due to better working capital management.
    Show source
    Better working capital management led to strong generation of cash flow from operations of INR118 crores, which was around 51% of the EBITDA for the FY '25.
  • Ami Organics Limited's Specialty Chemical revenue declined around 11% sequentially in Q3 FY '25, primarily due to lower volume in its commodity Chemical business.
    Show source
    I would like to highlight that commodity chemical business saw strong volume growth of more than 25% during FY '25.
  • Ami Organics Limited's EBITDA for the quarter was INR85 crores, almost double compared with the same period last year. Replaced by a later filing.
  • Ami Organics Limited's EBITDA margin was 27.5%, up 835 basis points Y-o-Y and 257 basis points Q-o-Q, driven by expansion in gross margin as well as operating leverage. Replaced by a later filing.
  • Ami Organics Limited's revenue from operations for FY '25 crossed INR1,006.9 crore, growth of 40.3% year-over-year. Replaced by a later filing.

Money and capital

  • Ami Organics Limited's capex for this financial year stood at INR195 crores, primarily allocated to Ankleshwar site as well as solar and electrolyte additive projects.
    Show source
    On a capital expenditure side, capex for this financial year stood at INR195 crores, primarily allocated to Ankleshwar site as well as solar and electrolyte additive projects.
  • Ami Organics Limited's overall capex for the upcoming year is expected to be around INR200 crores.
    Show source
    Overall capex for the upcoming year is expected to be around INR200 crores.
  • Ami Organics Limited has sufficient cash on hand to fund its upcoming-year capex through QIP proceeds and internal accruals of FY '25.
    Show source
    And we have sufficient cash on hand to fund this capex through QIP proceeds and internal accruals of FY '25.
  • Ami Organics Limited's net cash and cash equivalents were INR249 crores.
    Show source
    Net cash and cash equivalents were at INR249 crores.

What it expects ahead

What management expects

  • Ami Organics Limited anticipates continued growth in its CDMO business in FY '26, bolstered by increasing demand and new CDMO contracts.
    Show source
    Looking ahead in FY '26, we anticipate continued growth in our CDMO business bolstered by increasing demand and new CDMO contracts.
  • Several molecules in Ami Organics Limited's core generic intermediates portfolio are expected to benefit from patent expiration in 2025 and 2026, driving further momentum.
    Show source
    On the generic side, as always, we have several molecules within our core generic intermediates portfolio that are expected to benefit from patent expiration in 2025 and 2026, driving further momentum.
  • Ami Organics Limited is confident of delivering 25% revenue growth in FY '26.
    Show source
    Page 4 of 16 AMI Organics Limited May 02, 2025 Before I conclude, I want to reaffirm our confidence in delivering 25% revenue growth in FY '26, a milestone we have consistently achieved for the past 15 years.
  • Ami Organics Limited is committed to deliver further improvements in the margin in FY '26.
    Show source
    On the margin front, we are committed to deliver further improvements in the margin in FY '26.

What it is building and selling

Projects and capacity

  • Ami Organics Limited's electrolyte additives business is scheduled to commence production from a new brownfield plant at Jhagadia site in the second half of FY '26.
    Show source
    Page 3 of 16 AMI Organics Limited May 02, 2025 Additionally, our electrolyte additives business is scheduled to commence production from new brownfield plant at Jhagadia site in the second half of FY '26, with other business segments poised for steady advancement.
  • Ami Organics Limited will capitalize the remaining block, block 1, during the current quarter.
    Show source
    And I believe during the current quarter, we will capitalize the remaining block, i.e. block 1.
  • Ami Organics Limited is actively developing another 5 megawatts of solar power, expected to complete in near term and fulfil the electricity need of Sachin unit, Gujarat.
    Show source
    In addition to 10.8 megawatt power plant, we are actively developing another 5 megawatts.
  • Ami Organics Limited's 10.8 MW solar plant is projected to deliver substantial annual cost savings by meeting the majority of the electricity requirements for the Company's Ankleshwar and Jhagadia units in Gujarat.
    Show source
    A newly commissioned solar plant is projected to deliver substantial annual cost savings by meeting most of the electricity requirement of our company's Ankleshwar and Jhagadia units in Gujarat.
  • Ami Organics Limited's capex work at Ankleshwar site is almost completed.
    Show source
    Starting with Ankleshwar site, the capex work is almost completed.
  • Ami Organics Limited's capex for the upcoming year includes spillover capex of electrolyte additive business, maintenance capex and a new pilot plant facility at Sachin Surat; the pilot plant will help expedite scaling up of new products, manufacturing of high potent chemicals and new products under CRAM's model.
    Show source
    The capex for the full upcoming year, include spillover capex of electrolyte additive business, along with maintenance capex and new pilot plant facility at Sachin Surat.
Show 2 more statements

Demand and pricing

  • Pharmaceutical industries remain Ami Organics Limited's largest revenue contributor; demand for pharmaceutical intermediates remains stable, and the company is witnessing a notable increase in CMO/CDMO inquiries.
    Show source
    Demand for pharmaceutical intermediates remains stable, and we are witnessing a notable increase in CMO/CDMO inquiries.
  • India is increasingly recognized as a viable alternative to China, a trend Ami Organics Limited is strategically positioned to leverage.
    Show source
    Page 2 of 16 AMI Organics Limited May 02, 2025 India is increasingly recognized as a viable alternative to China, a trend that is strategically positioned us to leverage.

Risks, rules and outside factors

Rules and policy

  • Pharmaceuticals are exempted from U.S. tariffs. Replaced by a later filing.
    Show source
    On the policy front, pharmaceuticals are exempted from U.S. tariffs.

Everything else said on the call

Group structure

  • Management decided to rename Ami Organics Limited to Acutaas Chemicals Limited.
    Show source
    To support this transformation, the management has decided the strategic decision to rename the company from Ami Organics Limited to Acutaas Chemicals Limited.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Jason Soans: Sure, sir. And sir, just lastly, I wanted to know, you mentioned about the capex for FY '26. So you also mentioned 3 parts to it, spillover capex for Ankleshwar; solar power plant, which we are, I think, increasing or putting up a 5-megawatt more in the solar side; and a Sachin pilot plant. So sir, could you give a breakup for this? And I just wanted to know more about the Sachin pilot plant. What do you exactly want to do there? And could you give more color on this? Management: So we have our own pilot plant, which is going on very well, but more demand and more product are coming into the pipelines. And we'll be scaling up, we need to expand our pilot plant as well to support

    Answer, krishan parwani

    These batches were finished and now qualification stage is going on. So we are on track for the time being on that area.

Questions about this call

When was the Acutaas Chemicals Q4 FY25 earnings call transcript filed?
Acutaas Chemicals filed the transcript with the exchange on 8 May 2025. This page is built from that transcript.
What does this page list?
34 statements from the transcript across 7 topics, 23 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 1 question and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Acutaas Chemicals Q4 FY25 concall: Ami Organics Limited anticipates continued growth in its CDMO business in FY '26, bolstered by increasing demand and new CDMO contracts · DalalOS